Recent

% | $
Quotes you view appear here for quick access.

ChromaDex Corporation Message Board

cl124cl 682 posts  |  Last Activity: 10 hours ago Member since: Jun 30, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Infected Message Board

    by opkotunist 13 hours ago

    They certainly have some severe mental problems, anybody that would make a lying fool of themselves, needs some help. They should cut back on their drug intake and get some professional aid.

    C L

  • I like your plan Arby, but might add, if it gets below 35 cents. Hard to predict what these micro caps will do., or when..

    C L

  • Reply to

    ????

    by lwest0721 21 hours ago

    Hard to tell.. I think the whole setup resembles COCP, also a Doc Frost horse trading deal. It didn't do much until after the Nov. merger, then in Feb, it took off. I never did understand what sparked it to run, when it did.

    Seems to me, you just have to buy what Frost buys and then just sit on it.

    C L

  • Reply to

    My last buy was at $14.20,

    by cl124cl Apr 17, 2015 1:18 PM
    cl124cl cl124cl Apr 17, 2015 2:30 PM Flag

    Sure is easy, making money off of the elmoronos..

    C L

  • Reply to

    My last buy was at $14.20,

    by cl124cl Apr 17, 2015 1:18 PM
    cl124cl cl124cl Apr 17, 2015 2:15 PM Flag

    Good job, they just filled it.

    C L

  • if you losers can get it back down there, I'll take another 1K..

    C L

  • Reply to

    Frost in April (cont)

    by icemandios Apr 17, 2015 9:01 AM
    cl124cl cl124cl Apr 17, 2015 10:42 AM Flag

    Might be his wife's astrologer recommendations, or something like that.

    C L

  • good luck with that.

    C L

  • cl124cl by cl124cl Apr 17, 2015 8:51 AM Flag

    LEVON RESOURCES $ 0.39 LVNVF -0.01

    Daily Short Sale Volume
    view

    Short Interest (Shares Short)
    60,900

    Days To Cover (Short Interest Ratio)
    0.1

    Short Percent of Float
    %

    Short Interest - Prior
    10,800
    --------------------------------------------
    Looks like silverlolife has shorted 50,000 shares of the stock - what a loser.

    C L

  • Reply to

    TSRO gets upgrade

    by cl124cl Apr 16, 2015 4:14 PM
    cl124cl cl124cl Apr 16, 2015 5:40 PM Flag

    Charles, at one time Opie had some TSRO stock, they may still have a small amount, Burnaka would know...

    We def will be getting a lot of cash from them.

    C L

  • Jefferies Group Boosts TESARO Price Target to $70.00 (TSRO)
    April 16th, 2015 • by ABMN Staff
    Investment analysts at Jefferies Group boosted their price target on shares of TESARO (NASDAQ:TSRO) from $49.00 to $70.00 in a note issued to investors on Thursday. The firm currently has a “buy” rating on the stock. Jefferies Group’s price target suggests a potential upside of 18.95% from the stock’s previous close.
    Other equities research analysts have also recently issued reports about the stock. Analysts at Mizuho raised their price target on shares of TESARO from $50.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, April 1st. Separately, analysts at Citigroup Inc. raised their price target on shares of TESARO from $51.00 to $79.00 and gave the company a “buy” rating in a research note on Monday, February 23rd.
    Shares of TESARO (NASDAQ:TSRO) opened at 58.88 on Thursday. TESARO has a 52-week low of $22.15 and a 52-week high of $62.25. The stock has a 50-day moving average of $56. and a 200-day moving average of $39.. The company’s market cap is $2.13 billion.
    TESARO (NASDAQ:TSRO) last announced its earnings results on Thursday, February 19th. The company reported ($1.33) earnings per share for the quarter, missing the analysts’ consensus estimate of ($1.03) by $0.30. During the same quarter last year, the company posted ($0.72) earnings per share. On average, analysts predict that TESARO will post $-5.16 earnings per share for the current fiscal year.
    TESARO, Inc (NASDAQ:TSRO) is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company’s marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells.
    ________________________________________

    • The New Drug Application (NDA) for oral rolapitant is under rev

  • Reply to

    Small-Cap Lesson of the Week:

    by dk1949 Apr 16, 2015 12:40 PM
    cl124cl cl124cl Apr 16, 2015 1:24 PM Flag

    Good post, DK.. They make huge gyrations, and the reasons seldom become apparent.

    C L

  • Reply to

    All the biotechs I own,

    by cl124cl Apr 16, 2015 10:34 AM
    cl124cl cl124cl Apr 16, 2015 12:55 PM Flag

    Burnaka, you never know what's next.. Usually they go up if I don't buy and vise-versa.

    I was trading CRIS and making big bucks - missed the last run.

    C L

  • went dead about 2 weeks ago... Just range trading, and the ranges are getting tighter.

    C L

  • Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
    K. Jordan, F. Jahn and M. Aapro
    Correspondence to: Dr Karin Jordan, Department for Hematology/Oncology, Martin Luther University Halle-Wittenberg, Ernst-Grube-Str. 40, Halle 06120, Germany. Tel: +49-345-557-2019; Fax: +49-345-557-2950; E-mail: karin.jordan@uk-halle.de
    Received December 30, 2014.
    Revision received February 21, 2015.
    Accepted March 3, 2015.
    Abstract
    The prevention of chemotherapy-induced nausea and vomiting (CINV) has been revolutionized over the past 25 years. Guideline-based treatment means that vomiting can be prevented in the majority, but not in all patients. Therefore, antiemetic research continues with the goal of optimizing CINV control for all patients. This comprehensive review summarizes the research efforts in this field over the past few years. Emerging from this research are two new antiemetic agents, netupitant/palonosetron, the first antiemetic combination agent and rolapitant, a new NK1RA. In addition, studies have evaluated the benefits of olanzapine and ginger, explored optimal combinations of agents for delayed CINV prevention, confirmed that dexamethasone-sparing regimens are effective, and demonstrated the value of NK1RAs in high-dose chemotherapy settings as well as with certain moderately emetogenic chemotherapies such as carboplatin. Research has also validated the correlation between antiemetic guideline adherence and improved CINV control. Finally, regulatory authorities have utilized extreme caution in retiring some 5-HT3RAs or decreasing their maximum dose.

  • Reply to

    Vitamin D

    by craigsa620 Apr 15, 2015 8:09 PM
    cl124cl cl124cl Apr 15, 2015 8:43 PM Flag

    Newswise — SAN DIEGO, CA (March 16, 2015) - Researchers at UC San Diego and Creighton University have challenged the intake of vitamin D recommended by the National Academy of Sciences (NAS) Institute of Medicine (IOM), stating that their Recommended Dietary Allowance (RDA) for vitamin D underestimates the need by a factor of ten.
    In a letter1 published last week in the journal Nutrients the scientists confirmed a calculation error noted by other investigators, by using a data set from a different population. Dr. Cedric F. Garland, Dr.P.H., adjunct professor at UC San Diego’s Department of Family Medicine and Public Health said his group was able to confirm findings published by Dr. Paul Veugelers2 from the University of Alberta School of Public Health that were reported last October in the same journal.
    “Both these studies suggest that the IOM underestimated the requirement substantially,” said Garland. “The error has broad implications for public health regarding disease prevention and achieving the stated goal of ensuring that the whole population has enough vitamin D to maintain bone health.”
    The recommended intake of vitamin D specified by the IOM is 600 IU/day through age 70 years, and 800 IU/day for older ages. “Calculations by us and other researchers have shown that these doses are only about one-tenth those needed to cut incidence of diseases related to vitamin D deficiency,” Garland explained.
    Robert Heaney, M.D., of Creighton University wrote: "We call for the NAS-IOM and all public health authorities concerned with transmitting accurate nutritional information to the public to designate, as the RDA, a value of approximately 7,000 IU/day from all sources.”
    “This intake is well below the upper level intake specified by IOM as safe for teens and adults, 10,000 IU/day,” Garland said. Other authors were C. Baggerly and C. French, of GrassrootsHealth, a voluntary organization in San Diego CA, and E.D. Gorham, Ph.D., of UC San Diego.
    About GrassrootsHealth:

  • Reply to

    OPK gets new patent issued:

    by cl124cl Apr 15, 2015 5:50 PM
    cl124cl cl124cl Apr 15, 2015 6:11 PM Flag

    Sorry, forgot to attribute that to Uncle, came via email.

    C L

  • Title: Hypersulfated disaccharide formulations
    Document Type and Number: United States Patent 9006211
    Abstract:
    Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The compounds are formulated with agents that enhance the oral delivery of the hypersulfated disaccharides. The delivery agents are selected from the group consisting of natural or synthetic polymers having ionic side chains as well as other compounds or types of compounds that improve the bioavailability of the disaccharides relative to delivery of the drug without such agents. The hypersulfated disaccharides are made from heparin or salts thereof.
    Inventors: Ahmed, Tahir (Coral Gables, FL, US)
    Application Number: 14/011807
    Publication Date: 04/14/2015
    Filing Date: 08/28/2013
    Assignee: OPKO Health, Inc. (Miami, FL, US)
    Attorney, Agent or Firm: OPKO Health, Inc. Browder, Monte R.
    Excerpt:
    FIELD OF THE INVENTION
    The present invention relates to pharmaceutical formulations comprising a hypersulfated disaccharide compound of formula I as further described below and a delivery agent selected from a pharmaceutically acceptable vehicle (additive) that facilitates/enhances oral delivery of said compounds. The formulations are useful in the treatment of a variety of inflammatory disorders and diseases in animals and people, and, in particular, pulmonary disorders selected from asthma and other conditions or diseases associated with inflammation of the lungs and airway.

  • cl124cl cl124cl Apr 15, 2015 3:10 PM Flag

    brkdik mountain, think you have brianidjit all nailed down.

    C L

  • at 39 cents, may not do much until we get closer to mid-May. Volume has dropped, short-term traders off to somewhere else.

    C L

CDXC
1.20-0.03(-2.44%)Apr 17 3:36 PMEDT